Comparative Pharmacology
Head-to-head clinical analysis: NORCO versus SUBLIMAZE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORCO versus SUBLIMAZE PRESERVATIVE FREE.
NORCO vs SUBLIMAZE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORCO is a combination of hydrocodone, a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, particularly in the CNS, leading to decreased prostaglandin synthesis and antipyresis.
Fentanyl is a potent synthetic opioid agonist with primary action at the mu-opioid receptor. It induces analgesia, sedation, and respiratory depression by activating G-protein-coupled receptors that inhibit adenylyl cyclase, reduce cAMP production, and modulate ion channels (e.g., potassium efflux, calcium influx).
One tablet (5 mg hydrocodone/325 mg acetaminophen, 7.5 mg/325 mg, 10 mg/325 mg) orally every 4-6 hours as needed for pain. Maximum acetaminophen dose 4000 mg/day; maximum hydrocodone dose 60 mg/day.
IV: 0.5-2 mcg/kg bolus, may repeat q2-4h; or 0.5-1 mcg/kg/h infusion; IM: 0.5-2 mcg/kg q1-2h prn.
None Documented
None Documented
Hydrocodone: terminal elimination half-life is 3.8 to 6.0 hours (mean 4.5 hours) in adults; prolonged in hepatic or renal impairment. Acetaminophen: half-life 1.5–3 hours.
Terminal elimination half-life is 3-7 hours (mean 4.5 h) after IV administration, but may be prolonged (up to 12-15 h) in elderly, hepatic impairment, or after prolonged infusion due to redistribution.
Hydrocodone: primarily renal (approximately 60% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugated metabolites). Biliary/fecal excretion accounts for <10%.
Primarily renal: fentanyl and its metabolites are excreted in urine (~75%) and feces (~9%). Less than 10% excreted unchanged.
Category C
Category C
Opioid Analgesic
Opioid Analgesic